Small dog smiling while being held in Vet's arms

Join Dr. David Bruyette
for a VCA-exclusive CE training session

Verdinexor: A New Oral Treatment Option for Canine Lymphoma

How primary care teams can do more than ever for dogs with lymphoma

Sep 24, 2021

10:00 - 11:00 AM PT

1:00 - 2:00 PM ET

In this live, online CE session for VCA, Dr. Bruyette will review advancements and best practices for treating canine lymphoma.

You’ll learn about LAVERDIA-CA1, Anivive’s new oral tablet for lymphoma, and the novel SINE technology that makes it a targeted treatment. We’ll review clinical applications for LAVERDIA-CA1 and new treatment guidelines developed by a team of veterinary oncologists to optimize patient outcomes.

Hosted by

David Bruyette


Chief Medical Officer

Anivive Lifesciences

David Bruyette
You'll learn:
  • Evolving protocols for canine lymphoma treatment
  • The role of primary care teams in treating lymphoma
  • How SINE drugs work and why they are so different
  • When to consider LAVERDIA-CA1 for lymphoma patients
  • Guidelines to optimize patient outcomes

I acknowledge that by registering for this webinar Anivive may email me about this event and other events and news.

In adherence with RACE guidelines, CE certificates can only be distributed to individual attendees under the name used during registration. Group viewers will not receive multiple CE certificates